(SeaPRwire) –   CAMBRIDGE, Mass., May 6, 2026 — Nona Biosciences (“Nona” or the “Company”), a global biotechnology company focused on advancing biotherapeutic discovery through innovative technology platforms, today announced the appointment of Dr. Josh Xiao as Chief Scientific Officer (CSO). Dr. Xiao will be based in both the United States and China and will report directly to Dr. Di Hong, Chief Executive Officer of Nona Biosciences.

In this role, Dr. Xiao will lead the development of Nona’s global scientific strategy and oversee the continued evolution of its technology platforms, including Hu-mAtrIx^TM, the AI-driven drug discovery platform, with the goal of strengthening the company’s long-term competitive advantage through integrated technological capabilities and ecosystem collaboration. He will also guide the direction of scientific innovation and support the advancement of novel therapeutic approaches across multiple disease areas. Additionally, Dr. Xiao will provide leadership to Nona’s global Project Leaders (PLs), establishing a structured and scalable capability development framework to enhance project execution, deepen scientific insight into partner needs, and enable efficient integration of platform resources.

Dr. Xiao brings over 25 years of experience in drug discovery and leadership roles at both large biopharmaceutical companies and emerging biotechnology startups. He earned his Ph.D. in Biochemistry from Louisiana State University and completed postdoctoral training at Columbia University. Most recently, Dr. Xiao served as an entrepreneur in residence at RA Ventures, the healthcare incubator of RA Capital, and co-founded Starfish Medicines. Prior to that, he held scientific team leadership positions at Amgen, Tularik (acquired by Amgen), and Millennium Pharmaceuticals (acquired by Takeda), and led drug discovery functions at several startups. His expertise spans target discovery and validation, antibody discovery and engineering, translational medicine, and IND filing.

Dr. Di Hong, Chief Executive Officer of Nona Biosciences, commented: “We are very pleased to welcome Josh to Nona at a pivotal stage in our growth. His extensive experience in drug discovery and translational medicine, along with his strong track record in building high-performing scientific teams, will be instrumental as we continue to enhance our platform capabilities and strengthen our global scientific leadership. We believe he will further strengthen our ability to deliver high-quality innovation and create long-term value for our partners.”

“Nona Biosciences has been a leader in the discovery and development of fully human antibodies and multi-specifics using its proprietary H2L2 Harbour Mice^® platform, HCAb Harbour Mice^® platform, and Hu-mAtrIx^TM AI-driven drug discovery platform, enabling several new ‘antibody+’ therapeutic modalities,” said Dr. Josh Xiao, Chief Scientific Officer of Nona Biosciences. “I am thrilled to join the Nona Biosciences team and very excited to help strengthen and expand our technology platforms to support our partners’ success.”

About Nona Biosciences

Nona Biosciences is a global biotechnology company dedicated to advancing biotherapeutic innovation through cutting-edge technology platforms and integrated solutions. Nona supports programs with its I to I^® framework, guiding initiatives from early-stage concepts through preclinical research and progression toward Investigational New Drug (IND) applications and early clinical trials, covering target validation and antibody discovery to early development.

Nona’s proprietary Harbour Mice^® technology platform generates fully human monoclonal antibodies in both classical two light and two heavy chain (H2L2) format and heavy chain-only (HCAb) format. The HCAb Harbour Mice^® represents the world’s first fully human HCAb transgenic mouse with clinical validation. This unique platform offers exceptional versatility for diverse applications utilizing fully human VH single-domain antibodies as a plug-and-play system, including bispecific antibodies, multi-specific antibodies, CAR-T therapies, antibody-drug conjugates (ADCs), mRNA-based therapeutics, and more.

By integrating Harbour Mice^®, single-B cell screening technology, NonaCarFx^TM (a direct CAR-function-based screening platform), Hu-mAtrIx^TM (an AI-driven drug discovery platform), Modalities-on-Demand^® (a next-generation modalities solution), and comprehensive end-to-end preclinical drug development services, Nona Biosciences is committed to driving the global invention of transformative next-generation drugs. For more information, please visit: www.nonabio.com.

SOURCE Nona Biosciences